This is a new guideline from NICE on using dapagliflozin in patients with Type 1 diabetes. It was published in Aug 19.
Key learning points for me:
- There is a rise in the risk of ketoacidosis.
- It needs stopping if there is a sustained fall in GFR to < 45.
The main concern with using dapagliflozin alongside insulin in patients with Type 1 diabetes (T1DM) is that there is an almost two-fold rise in the risk of diabetic ketoacidosis. However the absolute risk is not that high. Because of this, quite rigid restrictions have been placed on who is eligible.